Chaudhary Pankaj, Marshall Thomas I, Perozziello Francesca M, Manti Lorenzo, Currell Frederick J, Hanton Fiona, McMahon Stephen J, Kavanagh Joy N, Cirrone Giuseppe Antonio Pablo, Romano Francesco, Prise Kevin M, Schettino Giuseppe
Centre for Cancer Research and Cell Biology, School of Medicine, Dentistry and Biomedical Sciences, Queen's University Belfast, Belfast, UK.
Department of Physics, University of Naples Federico II and INFN Naples Section University of Naples, Naples, Italy.
Int J Radiat Oncol Biol Phys. 2014 Sep 1;90(1):27-35. doi: 10.1016/j.ijrobp.2014.05.010. Epub 2014 Jun 28.
The biological optimization of proton therapy can be achieved only through a detailed evaluation of relative biological effectiveness (RBE) variations along the full range of the Bragg curve. The clinically used RBE value of 1.1 represents a broad average, which disregards the steep rise of linear energy transfer (LET) at the distal end of the spread-out Bragg peak (SOBP). With particular attention to the key endpoint of cell survival, our work presents a comparative investigation of cell killing RBE variations along monoenergetic (pristine) and modulated (SOBP) beams using human normal and radioresistant cells with the aim to investigate the RBE dependence on LET and intrinsic radiosensitvity.
Human fibroblasts (AG01522) and glioma (U87) cells were irradiated at 6 depth positions along pristine and modulated 62-MeV proton beams at the INFN-LNS (Catania, Italy). Cell killing RBE variations were measured using standard clonogenic assays and were further validated using Monte Carlo simulations and the local effect model (LEM).
We observed significant cell killing RBE variations along the proton beam path, particularly in the distal region showing strong dose dependence. Experimental RBE values were in excellent agreement with the LEM predicted values, indicating dose-averaged LET as a suitable predictor of proton biological effectiveness. Data were also used to validate a parameterized RBE model.
The predicted biological dose delivered to a tumor region, based on the variable RBE inferred from the data, varies significantly with respect to the clinically used constant RBE of 1.1. The significant RBE increase at the distal end suggests also a potential to enhance optimization of treatment modalities such as LET painting of hypoxic tumors. The study highlights the limitation of adoption of a constant RBE for proton therapy and suggests approaches for fast implementation of RBE models in treatment planning.
质子治疗的生物学优化只能通过详细评估布拉格曲线全范围内的相对生物学效应(RBE)变化来实现。临床使用的RBE值1.1是一个宽泛的平均值,它忽略了扩展布拉格峰(SOBP)远端线性能量传递(LET)的急剧上升。特别关注细胞存活的关键终点,我们的工作对使用人类正常细胞和抗辐射细胞的单能(原始)和调制(SOBP)束流的细胞杀伤RBE变化进行了比较研究,目的是研究RBE对LET和内在放射敏感性的依赖性。
在意大利卡塔尼亚的INFN-LNS,沿着原始和调制的62 MeV质子束的6个深度位置对人类成纤维细胞(AG01522)和胶质瘤(U87)细胞进行照射。使用标准克隆形成试验测量细胞杀伤RBE变化,并使用蒙特卡罗模拟和局部效应模型(LEM)进一步验证。
我们观察到沿质子束路径存在显著的细胞杀伤RBE变化,特别是在显示出强烈剂量依赖性的远端区域。实验RBE值与LEM预测值非常吻合,表明剂量平均LET是质子生物学效应的合适预测指标。数据还用于验证参数化RBE模型。
根据数据推断的可变RBE预测的传递到肿瘤区域的生物剂量,与临床使用的恒定RBE值1.1相比有显著差异。远端RBE的显著增加也表明有可能增强对治疗方式的优化,如对缺氧肿瘤进行LET扫描。该研究突出了质子治疗采用恒定RBE的局限性,并提出了在治疗计划中快速实施RBE模型的方法。